Propensity-matched analysis of adjuvant chemotherapy for completely resected Stage IB non-small-cell lung cancer patients
Lung cancer is the leading cause of cancer death worldwide [1]. Surgical resection is the main treatment of choice for early-stage non-small cell lung cancer (NSCLC) [2,3]. Tumor recurrence is the major cause of treatment failure after resection [4,5]. Beginning with the report of a significant survival difference related to receipt of adjuvant chemotherapy (ACT) from the International Adjuvant Lung Cancer Trial (IALT) [6], five multi-institutional randomized controlled trials (RCTs) have demonstrated statistically significant survival advantages associated with ACT for patients with completely resected NSCLC [6 –10].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Xiao Li, Chao Zhang, Zewen Sun, Fan Yang, Rongxin Xiao, Xizhao Sui, Guanchao Jiang, Wenzhao Zhong, Jun Wang Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Lung Cancer | Non-Small Cell Lung Cancer | Statistics